Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (6): 830-839.doi: 10.19982/j.issn.1000-6621.20260040
• Original Articles • Previous Articles Next Articles
Du Xilong1, Maiwulajiang·Yimamu 2, Na Yan1, Paziliya·Yasheng 1, Guo Gang3, Maiweilanjiang·Abulimiti 4, Zhang Liping5, Zheng Yanling5(
)
Received:2026-01-22
Online:2026-06-10
Published:2026-05-25
Contact:
Zheng Yanling
E-mail:zhengyl_math@sina.cn
Supported by:CLC Number:
Du Xilong, Maiwulajiang·Yimamu , Na Yan, Paziliya·Yasheng , Guo Gang, Maiweilanjiang·Abulimiti , Zhang Liping, Zheng Yanling. Construction of an optimal prediction model for treatment outcomes in retreatment pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2026, 48(6): 830-839. doi: 10.19982/j.issn.1000-6621.20260040
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20260040
| 因素 | 治疗成功(1154例) | 治疗失败(242例) | χ2值 | P值 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 性别 | 2.318 | 0.128 | ||||||||||
| 男性 | 574(81.07) | 134(18.93) | ||||||||||
| 女性 | 580(84.30) | 108(15.70) | ||||||||||
| 年龄组(岁) | 2.649 | 0.754 | ||||||||||
| ≤24 | 20(90.91) | 2(9.09) | ||||||||||
| 25~34 | 45(80.36) | 11(19.64) | ||||||||||
| 35~44 | 50(83.33) | 10(16.67) | ||||||||||
| 45~54 | 105(85.37) | 18(14.63) | ||||||||||
| 55~64 | 258(83.77) | 50(16.23) | ||||||||||
| ≥65 | 676(81.74) | 151(18.26) | ||||||||||
| 患者来源 | 26.880 | <0.001 | ||||||||||
| 健康体检 | 668(87.21) | 98(12.79) | ||||||||||
| 主动筛查 | 8(8/9) | 1(1/9) | ||||||||||
| 直接就诊 | 32(82.05) | 7(17.95) | ||||||||||
| 转诊 | 286(77.72) | 82(22.28) | ||||||||||
| 追踪 | 160(74.77) | 54(25.23) | ||||||||||
| 诊断分型 | - | 0.078 | ||||||||||
| 继发性肺结核 | 1130(83.03) | 231(16.97) | ||||||||||
| 结核性胸膜炎 | 19(67.86) | 9(32.14) | ||||||||||
| 气管及支气管结核 | 3(3/4) | 1(1/4) | ||||||||||
| 血行播散性肺结核 | 2(2/3) | 1(1/3) | ||||||||||
| 诊断结果 | 7.079 | 0.029 | ||||||||||
| 病原学阳性 | 755(81.80) | 168(18.20) | ||||||||||
| 病原学阴性 | 380(85.39) | 65(14.61) | ||||||||||
| 结核性胸膜炎 | 19(67.86) | 9(32.14) | ||||||||||
| 合并症 | 34.110 | <0.001 | ||||||||||
| 未知 | 683(84.84) | 122(15.16) | ||||||||||
| 无 | 359(84.87) | 64(15.13) | ||||||||||
| 有 | 112(66.67) | 56(33.33) | ||||||||||
| 糖尿病 | 34.462 | <0.001 | ||||||||||
| 无 | 1083(84.48) | 199(15.52) | ||||||||||
| 有 | 71(62.28) | 43(37.72) | ||||||||||
| 其他合并症 | 1.325 | 0.250 | ||||||||||
| 无 | 1113(82.94) | 229(17.06) | ||||||||||
| 有 | 41(75.93) | 13(24.07) | ||||||||||
| 治疗方案 | - | <0.001 | ||||||||||
| 2H-R-Z-E/10H-R-E | 116(63.39) | 67(36.61) | ||||||||||
| 2H-R-Z-E/4H-R | 977(86.54) | 152(13.46) | ||||||||||
| 2H-R-Z-E/7~10H-R-E | 45(81.82) | 10(18.18) | ||||||||||
| 6~9R-Z-E-Lfx | 4(4/5) | 1(1/5) | ||||||||||
| 其他治疗方案 | 12(50.00) | 12(50.00) | ||||||||||
| 治疗模式 | 13.366 | 0.001 | ||||||||||
| 门诊治疗 | 271(76.55) | 83(23.45) | ||||||||||
| 未知 | 604(85.55) | 102(14.45) | ||||||||||
| 住院治疗 | 279(83.04) | 57(16.96) | ||||||||||
| 实际服药管理方式 | 34.662 | <0.001 | ||||||||||
| 未知 | 0(0/7) | 7(7/7) | ||||||||||
| 医务人员管理 | 915(83.64) | 179(16.36) | ||||||||||
| 智能工具 | 239(81.02) | 56(18.98) | ||||||||||
| 0月序痰检 | 37.584 | <0.001 | ||||||||||
| 未查 | 3(23.08) | 10(76.92) | ||||||||||
| 阳性 | 204(78.46) | 56(21.54) | ||||||||||
| 阴性 | 947(84.33) | 176(15.67) | ||||||||||
| 2月序痰检 | 370.755 | <0.001 | ||||||||||
| 未查 | 15(14.42) | 89(85.58) | ||||||||||
| 阳性 | 6(60.00) | 4(40.00) | ||||||||||
| 阴性 | 1133(88.38) | 149(11.62) | ||||||||||
| 痰培养 | 48.727 | <0.001 | ||||||||||
| 未查 | 209(69.21) | 93(30.79) | ||||||||||
| 阳性 | 455(86.50) | 71(13.50) | ||||||||||
| 阴性 | 490(86.27) | 78(13.73) | ||||||||||
| 影像学 | 4.825 | 0.028 | ||||||||||
| 未查 | 772(81.09) | 180(18.91) | ||||||||||
| 异常 | 382(86.04) | 62(13.96) | ||||||||||
| 分子生物学检测 | 8.289 | 0.015 | ||||||||||
| 未查 | 6(66.67) | 3(33.33) | ||||||||||
| 阳性 | 640(80.50) | 155(19.50) | ||||||||||
| 阴性 | 508(85.81) | 84(14.19) | ||||||||||
| 病原学检测 | 1.143 | 0.285 | ||||||||||
| 阳性 | 757(81.84) | 168(18.16) | ||||||||||
| 阴性 | 397(84.29) | 74(15.71) | ||||||||||
| 药物敏感性试验 | - | <0.001 | ||||||||||
| 利福平耐药 | 4(9.09) | 40(90.91) | ||||||||||
| 耐多药 | 0(0/9) | 9(9/9) | ||||||||||
| 未查 | 404(84.52) | 74(15.48) | ||||||||||
| 敏感 | 740(86.15) | 119(13.85) | ||||||||||
| 异烟肼耐药 | 6(6/6) | 0(0/6) | ||||||||||
| 菌种鉴定 | 1.933 | 0.380 | ||||||||||
| 结核分枝杆菌 | 743(81.65) | 167(18.35) | ||||||||||
| 未查 | 404(84.52) | 74(15.48) | ||||||||||
| 未检测到分枝杆菌 | 7(7/8) | 1(1/8) | ||||||||||
| HIV检查 | - | 0.317 | ||||||||||
| 阳性 | 1(50.00) | 1(50.00) | ||||||||||
| 阴性 | 1153(82.71) | 24(17.29) | ||||||||||
| 排序 | 特征变量 | 平均准确 率下降量 | 筛选 结果 |
|---|---|---|---|
| 1 | 2月序痰检 | 0.901 | 保留 |
| 2 | 药物敏感性试验 | 0.348 | 保留 |
| 3 | 治疗方案 | 0.304 | 保留 |
| 4 | 实际服药管理方式 | 0.211 | 保留 |
| 5 | 患者来源 | 0.179 | 保留 |
| 6 | 糖尿病 | 0.160 | 保留 |
| 7 | 治疗模式 | 0.158 | 保留 |
| 8 | 菌种鉴定 | 0.143 | 保留 |
| 9 | 分子生物学检测 | 0.133 | 保留 |
| 10 | 痰培养 | 0.122 | 保留 |
| 11 | 诊断 | 0.115 | 保留 |
| 12 | 病原学 | 0.113 | 保留 |
| 13 | 合并症 | 0.083 | 保留 |
| 14 | 影像学 | 0.055 | 保留 |
| 15 | 诊断分型 | 0.051 | 排除 |
| 16 | 0月序痰检 | 0.041 | 排除 |
| 17 | HIV检查 | 0.036 | 排除 |
| 18 | 其他合并症 | 0.005 | 排除 |
| 19 | 年龄 | -0.006 | 保留 |
| 20 | 性别 | -0.040 | 保留 |
| 模型 | 准确率(%) | 精确率(%) | 召回率(%) | F1分数 | AUC | AP |
|---|---|---|---|---|---|---|
| 逻辑回归 | 84.0 | 86.0 | 84.0 | 0.847 | 0.814 | 0.923 |
| 支持向量机 | 84.4 | 86.2 | 84.4 | 0.851 | 0.829 | 0.946 |
| 决策树 | 81.8 | 83.7 | 81.8 | 0.826 | 0.739 | 0.902 |
| 随机森林 | 87.1 | 86.2 | 87.1 | 0.865 | 0.814 | 0.938 |
| XGBoost | 88.3 | 87.5 | 88.3 | 0.876 | 0.805 | 0.923 |
| LightGBM | 89.2 | 88.5 | 89.2 | 0.885 | 0.815 | 0.930 |
| 梯度提升树 | 88.0 | 87.1 | 88.0 | 0.871 | 0.843 | 0.945 |
| 多层感知机 | 89.0 | 88.4 | 89.0 | 0.886 | 0.807 | 0.931 |
| CatBoost | 89.2 | 88.5 | 89.2 | 0.885 | 0.829 | 0.941 |
| 排名 | 特征 | SHAP分析 | CatBoost模型 | ||
|---|---|---|---|---|---|
| MeanSHAP绝对值 | 重要性贡献(%) | 重要性得分值 | 重要性贡献(%) | ||
| 1 | 2月序痰检 | 0.595 | 22.10 | 12.782 | 17.60 |
| 2 | 治疗方案 | 0.367 | 13.60 | 12.104 | 16.70 |
| 3 | 治疗模式 | 0.290 | 10.80 | 10.618 | 14.60 |
| 4 | 合并症 | 0.280 | 10.40 | 9.544 | 13.10 |
| 5 | 患者来源 | 0.278 | 10.30 | 12.318 | 16.90 |
| 6 | 年龄 | 0.231 | 8.60 | 8.457 | 11.60 |
| 7 | 药物敏感性试验 | 0.204 | 7.60 | 8.948 | 12.30 |
| 8 | 实际服药管理方式 | 0.157 | 5.80 | 8.092 | 11.10 |
| 9 | 痰培养结果 | 0.136 | 5.10 | 8.812 | 12.10 |
| 10 | 影像学结果 | 0.105 | 3.90 | 4.799 | 6.60 |
| 11 | 性别 | 0.072 | 2.70 | 3.525 | 4.80 |
| 特征 | 类别 | 样本 例数 | 平均 SHAP值 |
|---|---|---|---|
| 2月序痰检 | 阴性 | 381 | 0.306 |
| 阳性 | 2 | -0.993 | |
| 未查 | 35 | -3.830 | |
| 合并症 | 无 | 128 | 0.461 |
| 有 | 45 | -0.132 | |
| 未知 | 245 | -0.214 | |
| 实际服药管理方式 | 医务人员管理 | 313 | 0.081 |
| 智能工具 | 103 | -0.293 | |
| 未知 | 2 | -1.292 | |
| 年龄组(岁) | ≤24 | 4 | 0.862 |
| 25~34 | 17 | 0.475 | |
| 35~44 | 23 | 0.525 | |
| 45~54 | 38 | 0.467 | |
| 55~64 | 93 | 0.099 | |
| ≥65 | 243 | -0.192 | |
| 患者来源 | 健康体检 | 238 | 0.242 |
| 主动筛查 | 3 | 0.231 | |
| 直接就诊 | 12 | 0.037 | |
| 转诊 | 101 | -0.215 | |
| 追踪 | 64 | -0.523 | |
| 治疗方案 | 2H-R-Z-E/4H-R | 348 | 0.238 |
| 6~9R-Z-E-Lfx | 1 | -0.006 | |
| 2H-R-Z-E/7~10H-R-E | 13 | -0.032 | |
| 其他敏感方案 | 7 | -0.547 | |
| 2H-R-Z-E/10H-R-E | 49 | -1.338 | |
| 治疗模式 | 未知 | 229 | 0.292 |
| 住院治疗 | 102 | -0.003 | |
| 门诊治疗 | 87 | -0.476 | |
| 痰培养结果 | 阴性 | 171 | 0.074 |
| 阳性 | 157 | 0.022 | |
| 未查 | 90 | -0.146 | |
| 药敏试验结果 | 异烟肼耐药 | 1 | 0.245 |
| 未查 | 148 | 0.131 | |
| 异烟肼和利福平均敏感 | 250 | 0.053 | |
| 耐多药 | 4 | -0.694 | |
| 利福平耐药 | 15 | -2.056 |
| [1] | 上海市感染性疾病(结核病)临床医学研究中心/同济大学附属上海市肺科医院, 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 中国防痨协会, 等. 复治肺结核病诊断和治疗专家共识. 中国防痨杂志, 2021, 43(12): 1226-1238. doi:10.3969/j.issn.1000-6621.2021.12.002. |
| [2] | Debit A, Poulet C, Josse C, et al. Assessing Random Forest self-reproducibility for optimal short biomarker signature discovery. Brief Bioinform, 2025, 26(4): bbaf318. doi:10.1093/bib/bbaf318. |
| [3] | Morgan RD, Youssi BW, Cacao R, et al. Random Forest Prognostication of Survival and 6-Month Outcome in Pediatric Patients Following Decompressive Craniectomy for Traumatic Brain Injury. World Neurosurg, 2025, 193: 861-867. doi:10.1016/j.wneu.2024.10.075. |
| [4] | Taye EA, Woubet EY, Hailie GY, et al. Random forest algorithm for predicting tobacco use and identifying determinants among pregnant women in 26 sub-Saharan African countries: a 2024 analysis. BMC Public Health, 2025, 25(1): 1506. doi:10.1186/s12889-025-22794-1. |
| [5] | Kuang X, Wang F, Hernandez KM, et al. Accurate and rapid prediction of tuberculosis drug resistance from genome sequence data using traditional machine learning algorithms and CNN. Sci Rep, 2022, 12(1): 2427. doi:10.1038/s41598-022-06449-4. |
| [6] | Sarker P, Choi K, Nahid AA, et al. CatBoost with physics-based metaheuristics for thyroid cancer recurrence prediction. BioData Min, 2025, 18(1): 84. doi:10.1186/s13040-025-00494-1. |
| [7] | Saeys Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics. Bioinformatics, 2007, 23(19): 2507-2517. doi:10.1093/bioinformatics/btm344. |
| [8] | Liang D, Wang L, Zhong P, et al. Perspective: Global Burden of Iodine Deficiency: Insights and Projections to 2050 Using XGBoost and SHAP. Adv Nutr, 2025, 16(3): 100384. doi:10.1016/j.advnut.2025.100384. |
| [9] | Han Y, Xie X, Qiu J, et al. Early prediction of sepsis associated encephalopathy in elderly ICU patients using machine learning models: a retrospective study based on the MIMIC-IV database. Front Cell Infect Microbiol, 2025, 15: 1545979. doi:10.3389/fcimb.2025.1545979. |
| [10] | Wu J, Tao G, Xie S, et al. Prediction of three-year all-cause mortality in patients with heart failure and atrial fibrillation using the CatBoost model. BMC Cardiovasc Disord, 2025, 25(1): 466. doi:10.1186/s12872-025-04928-w. |
| [11] | Huang C, Wei Y, Deng L, et al. Research on the prediction of slow blood flow in pPCI of STEMI patients based on CatBoost. Eur J Med Res, 2025, 30(1): 1152. doi:10.1186/s40001-025-03406-5. |
| [12] | Nakaya M, Kamishima M, Yamaoka T, et al. Real-world data on combination treatment with bedaquiline in patients with multidrug-resistant pulmonary tuberculosis in Japan: An interim analysis of post-marketing surveillance. J Infect Chemother, 2025, 31(4): 102661. doi:10.1016/j.jiac.2025.102661. |
| [13] | Bamorovat M, Sharifi I, Agha Kuchak Afshari S, et al. Mutual Role of Patients and the Healthcare System in the Control of Cutaneous Leishmaniasis. Transbound Emerg Dis, 2023, 2023: 7814940. doi:10.1155/2023/7814940. |
| [14] | Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis, 2023: ciad428. doi:10.1093/cid/ciad428. |
| [15] | Salnikova A, Makarenko O, Sereda Y, et al. Depression among people living with tuberculosis and tuberculosis/HIV coinfection in Ukraine: a cross-sectional study. Glob Health Action, 2025, 18(1): 2448894. doi:10.1080/16549716.2024.2448894. |
| [16] | Hinay AA Jr, Mamalintaw MA, Damasin JML, et al. Sociodemographic and Clinical Predictors of Tuberculosis and Unsuccessful Treatment Outcomes in Davao City, Philippines: A Retrospective Cohort Study. Int J Environ Res Public Health, 2025, 22(7): 1154. doi:10.3390/ijerph22071154. |
| [17] | 王瑞华, 杨雨晴, 张洪昌, 等. 2014—2024年山东省泰安市肺结核流行特征及发病趋势预测. 结核与肺部疾病杂志, 2026, 7(2):194-202. doi:10.19983/j.issn.2096-8493.20250212. |
| [18] | Rodriguez CA, Lodi S, Horsburgh CR, et al. Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion. PLoS One, 2022, 17(11): e0276457. doi:10.1371/journal.pone.0276457. |
| [19] | Gao F, Zhang J, Deng J, et al. Clinical manifestations, treatment and prognosis of juvenile idiopathic arthritis with pulmonary involvement in China: a single centre study. Clin Exp Rheumatol, 2024, 42(11): 2303-2311. doi:10.55563/clinexprheumatol/udjbtq. |
| [20] | Fakhari A, Shalchi B, Rahimi VA, et al. Mental health literacy and COVID-19 related stress: The mediating role of healthy lifestyle in Tabriz. Heliyon, 2023, 9(7): e18152. doi:10.1016/j.heliyon.2023.e18152. |
| [21] | Mbuh TP, Mendjime P, Goupeyou-Wandji IA, et al. Trends of drug-resistant tuberculosis and risk factors to poor treatment-outcome: a database analysis in Littoral region-Cameroon, 2013-2022. BMC Public Health, 2024, 24(1): 3195. doi:10.1186/s12889-024-20585-8. |
| [22] | 孙慧娟, 苏伟, 陈伟. 利福平耐药结核病患者不良治疗结局及其影响因素研究进展. 结核与肺部疾病杂志, 2024, 5(6): 573-582. doi:10.19983/j.issn.2096-8493.2024111. |
| [23] | 侯坤, 伍劲屹, 王晓君, 等. 武汉市某综合医院肺结核诊断延迟影响因素及风险预测研究. 结核与肺部疾病杂志, 2025, 6(3):316-322. doi:10.19983/j.issn.2096-8493.20250069. |
| [24] | Bariz H, Stanikzai MH, Mudaser GM, et al. Diagnostic Delay and its Predictors among Tuberculosis Patients in Kandahar, Afghanistan: A Cross-sectional Analytical Study. Int J Mycobacteriol, 2025, 14(3): 232-238. doi:10.4103/ijmy.ijmy_91_25. |
| [1] | Reyhangul·Aken , Muratjan·Amat , Gao Xusheng, Ding Caihong, Zeng Yi, Chen Yu, Bai Yan, Fan Lin. Analysis of influencing factors of malnutrition and treatment outcomes among elderly patients with pulmonary tuberculosis aged 60 years and above [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 751-759. |
| [2] | Liu Lin, Yin Xiaocheng, Zhang Xiaofo, Liang Linlong, Yang Ju. Global burden of tuberculosis in children aged 0-14 years, 1990—2023, and trend projections for 2024—2050 [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 840-848. |
| [3] | Yuan Shaoying, Cui Zhongfeng, Du Jiang, Cao Xuefang, Feng Boxuan, He Yijun, Li Zihan, Zhao Yaqi, Yu Yilin, Gao Lei, Xin He’nan, Li Hongzhi. The application value of the QuantiFERON-TB Gold Plus for active pulmonary tuberculosis diagnosis and treatment response monitoring [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 865-873. |
| [4] | Qiu Yuxian, Huang Fang, Yang Xiaoyi, Yang Feng, Lu Hua, Zhang Tianyi, Zhang Yang, Yao Rong, Li Yuanyuan. Research progress in digital twin technology for tuberculosis patient management [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 550-555. |
| [5] | Wang Jing, Jing Wei, Li Weiwen, Zhu Qingdong, Pang Yu, Chu Naihui, Nie Wenjuan. Clinical cohort analysis of the efficacy and safety of extended-course bedaquiline in patients with multidrug-resistant/rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 313-319. |
| [6] | Wei Liuying, Wu Xingxing, Huang Lianpiao, Zeng Chunmei, Zhao Chunyan, Song Chang, Nie Wenjuan, Pei Jie, Wei Xiaoying, Huang Aichun, Zhu Qingdong, Xie Zhouhua, Huang Xianzhen. Analysis of the application effect of compound balanced nutrition powder in anti-tuberculosis treatment on multidrug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 349-355. |
| [7] | Shang Yuanyuan, Nie Wenjuan, Chu Naihui. Comparison of clinical characteristics and prognostic factors between elderly and non-elderly patients with Mycobacterium abscessus pulmonary disease [J]. Chinese Journal of Antituberculosis, 2026, 48(1): 106-112. |
| [8] | Reyihanguli Aken, Fan Lin. Research progress on the impact of malnutrition on the treatment outcomes of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2026, 48(1): 153-159. |
| [9] | Tian Xiaomei, Jiang Xuefeng, Yang Xia, Sha Xiaolan, Lei Juan, Wang Xiaowei, Liu Jing. Analysis of case detection and anti-tuberculosis treatment outcomes in Mycobacterium tuberculosis/HIV co-infected patients in Ningxia from 2015 to 2023 [J]. Chinese Journal of Antituberculosis, 2026, 48(1): 57-63. |
| [10] | Chen Depan, Li Xiang, Zhang Kaiyi, Li Min, Xia Jiawei, Gao ChuYi, Yang Yatao, Zhang Le. To construct a risk prediction model for adult chronic kidney disease complicated with active tuberculosis based on logistic regression, decision tree, and neural network [J]. Chinese Journal of Antituberculosis, 2026, 48(1): 94-105. |
| [11] | Zhang Yaning, Yang Peirong, Yan Chuanyuan, Li Hongbing, Xiao Yuyu, Zhang Lu. Construction and validation of a prediction model for pulmonary tuberculosis-affected households facing catastrophic costs in Baoji City [J]. Chinese Journal of Antituberculosis, 2025, 47(9): 1171-1179. |
| [12] | Ren Hangkong, Sun Weifeng, Wang Linbao. Analysis of surgery effectiveness in treating chronic cavitary lung disease [J]. Chinese Journal of Antituberculosis, 2025, 47(9): 1180-1186. |
| [13] | Abuduresuli Tu’ersun, Abudukeyoumujiang Abulizi, Patiman Maimaiti, Huang Chencui, Shen Lingyan, Mayidili Nijiati. Predicting pulmonary tuberculosis treatment outcomes using longitudinal chest CT radiomics and deep learning [J]. Chinese Journal of Antituberculosis, 2025, 47(8): 1044-1052. |
| [14] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
| [15] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.